Cryotherapy News and Research

RSS
Cryotherapy is the application of extreme cold to freeze and destroy tumors and has proven to be an effective and minimally invasive technology that results in minimal pain, rapid recovery and high quality of life for patients.
Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Review affirms hand therapy as one of most vital treatment steps in recovery from hand injury surgery

Review affirms hand therapy as one of most vital treatment steps in recovery from hand injury surgery

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

Vanderbilt Medical Center treats first patient in Galil Medical's new TRACE renal registry

Vanderbilt Medical Center treats first patient in Galil Medical's new TRACE renal registry

Experts call on international community to commit attention and resources to cervical cancer prevention

Experts call on international community to commit attention and resources to cervical cancer prevention

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

New treatment modalities for RCC

New treatment modalities for RCC

CryoSTAT cold therapy for hemorrhoids

CryoSTAT cold therapy for hemorrhoids

Surgery still the only measure to cure RCC

Surgery still the only measure to cure RCC

Single-incision laparoscopy reduces postoperative complications

Single-incision laparoscopy reduces postoperative complications

Cryotherapy may become the future treatment for cancer

Cryotherapy may become the future treatment for cancer

Cryotherapy offers potential treatment options for breast cancer patients

Cryotherapy offers potential treatment options for breast cancer patients

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

Acculis' new device for destroying unwanted tissues receives European CE Mark clearance

Acculis' new device for destroying unwanted tissues receives European CE Mark clearance

Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint

Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

U.S. market for urological devices to reach over $5.4 billion in 2016

U.S. market for urological devices to reach over $5.4 billion in 2016

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada approves Zyclara Cream for multiple actinic keratoses

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

Sangretech Biomedical signs amended license agreement with Bostwick Laboratories

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.